Part 01 · The Question→Part 02 · The Record→Part 03 · The File
← All Case Files
Inspection Case File · CF04 · Sterile Manufacturing

Deviation Risk Disposition: The 483 Most Teams Don't See Coming.

A documented deviation. A signed CAPA. A closed investigation. And a single question, asked on day two of inspection, that the file does not answer.

What you'll see in this case file
  • The exact 483 observation language
  • The five required authorization fields
  • A complete reference DDR record
  • The blank template for your facility
See What Defensible Looks Like → Free to read. No payment to continue.
Citation · 21 CFR 211.113 ICH · Q9 Used by Quality leaders preparing for FDA inspections
The Scene

Day two of the inspection.

. The investigator pulls Deviation Report DR-2024-0287. Levofloxacin Injection 500 mg, Lot 2024-0512. An environmental monitoring action level was exceeded in Grade B during the aseptic fill on May 14, 2024.

The investigation was thorough. The impact assessment concluded the deviation did not impact product quality. CAPA was opened to investigate the EM trend. The lot was released.

The investigator turns to the conclusion.

Investigator
"No impact to product quality."
She reads the conclusion twice. Then she sets the file down and looks up.
Investigator
"Who authorized this no-impact conclusion? What evidence specifically supported the determination? Which other lots filled in the same shift were considered? And on what risk-based standard was the residual contamination risk deemed acceptable?"
She listens to the verbal answer. Then she asks for the documented reasoning.
Pause

Most QA teams answer this question verbally. The file does not contain the documented reasoning. That is the gap.

Skip ahead to the record format →
Why this matters now

FDA inspections under Annex 1 alignment are increasingly focused on no-impact conclusions for sterile manufacturing deviations. Reports that document the assessment but not the conclusion logic create exposure that retrospective justification cannot close.

What the file contained

The deviation report was complete. The impact assessment was thorough. The CAPA was opened.

Environmental monitoring data was reviewed. The aseptic fill was reviewed. The lot release process was followed. The Quality Assurance Director signed the disposition.

What the file contained was the conclusion.

What the file did not contain was the decision.

An impact assessment was performed. A no-impact conclusion was reached. A signature appeared on the disposition. But the rationale for treating the EM excursion as non-impacting, the documented exclusion of contamination risk to the affected lot and adjacent lots, and the named individual who authorized the conclusion are not in the file.

The conclusion belongs in the file. The decision belongs in the record.

What the investigator is evaluating
21 CFR 211.113 requires assessment of risk to product. The standard is not whether the team performed an impact assessment. The standard is whether the no-impact conclusion was authorized on a documented basis.

For sterile products under combined CGMP and Annex 1 expectations, the standard is strict: an EM excursion in Grade B during aseptic operations creates a documented contamination risk, and any conclusion of no-impact must demonstrate — in writing — how that risk was evaluated and dispositioned.

The assessment must demonstrate — in writing, contemporaneous with the conclusion — that contamination risk was evaluated, that adjacent lots were formally considered, and that the named authorizing individual reviewed the totality of evidence before concluding no impact.

An impact assessment template completed is data. A completed template is not, on its own, a documented no-impact conclusion.

Investigator
"I am not asking whether your team concluded no impact. I am asking whether the no-impact conclusion was authorized — and on what evidentiary basis."
The QA Director cannot produce the record.
The Gap

The lot may have been free of contamination. The report does not show the work behind the no-impact conclusion.

The deviation file documents the EM excursion. It does not document who decided this had no impact, on what evidence, against what alternatives, and under what authority.

Ready to see the record format?
See the five fields the investigator expects to find →
The 483
"Failure to document the scientific and risk-based rationale used to justify the conclusion that the deviation did not impact product quality, resulting in an inability to reconstruct the basis for the disposition decision during inspection. The deviation closure record establishes that the deviation was investigated but does not establish how the no-impact conclusion was reached."
21 CFR 211.113 — applied regulatory framework.
Continued · Part 02 of 03

That 483 was avoidable.

See the record that prevents it.

The five fields the investigator expects to find. The alternative-causes evaluation that distinguishes a decision from a signature. A complete reference example from the Vancomycin scenario.

Show Me the Record →
✓ Free to read · No payment required to continue

Used by Quality and Validation leaders preparing for FDA and EMA inspections. Built around 21 CFR 211.192 and ICH Q9.